Cancer immunotherapy

From the lab to clinical applications - Potential impact on cancer centres' organisation

Linda Cairns, Sandrine Aspeslagh, Andrea Anichini, Jon Amund Kyte, Christian Blank, Paolo Ascierto, Nicolle Rekers, Per Thor Straten, Ahmad Awada

Research output: Contribution to journalArticle

Abstract

This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

Original languageEnglish
Article number691
Journalecancermedicalscience
Volume10
DOIs
Publication statusPublished - Nov 9 2016

Fingerprint

Immunotherapy
Organizations
Neoplasms
Immune System
Belgium
Vaccines
Monoclonal Antibodies
T-Lymphocytes
Therapeutics
Research

Keywords

  • Cancer vaccines
  • Immunotherapy
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer immunotherapy : From the lab to clinical applications - Potential impact on cancer centres' organisation. / Cairns, Linda; Aspeslagh, Sandrine; Anichini, Andrea; Kyte, Jon Amund; Blank, Christian; Ascierto, Paolo; Rekers, Nicolle; Straten, Per Thor; Awada, Ahmad.

In: ecancermedicalscience, Vol. 10, 691, 09.11.2016.

Research output: Contribution to journalArticle

Cairns, Linda ; Aspeslagh, Sandrine ; Anichini, Andrea ; Kyte, Jon Amund ; Blank, Christian ; Ascierto, Paolo ; Rekers, Nicolle ; Straten, Per Thor ; Awada, Ahmad. / Cancer immunotherapy : From the lab to clinical applications - Potential impact on cancer centres' organisation. In: ecancermedicalscience. 2016 ; Vol. 10.
@article{e4e1088167e04c468ae931c980ee7a10,
title = "Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation",
abstract = "This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.",
keywords = "Cancer vaccines, Immunotherapy, Monoclonal antibodies",
author = "Linda Cairns and Sandrine Aspeslagh and Andrea Anichini and Kyte, {Jon Amund} and Christian Blank and Paolo Ascierto and Nicolle Rekers and Straten, {Per Thor} and Ahmad Awada",
year = "2016",
month = "11",
day = "9",
doi = "10.3332/ecancer.2016.691",
language = "English",
volume = "10",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Cancer immunotherapy

T2 - From the lab to clinical applications - Potential impact on cancer centres' organisation

AU - Cairns, Linda

AU - Aspeslagh, Sandrine

AU - Anichini, Andrea

AU - Kyte, Jon Amund

AU - Blank, Christian

AU - Ascierto, Paolo

AU - Rekers, Nicolle

AU - Straten, Per Thor

AU - Awada, Ahmad

PY - 2016/11/9

Y1 - 2016/11/9

N2 - This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

AB - This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

KW - Cancer vaccines

KW - Immunotherapy

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84996482869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996482869&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2016.691

DO - 10.3332/ecancer.2016.691

M3 - Article

VL - 10

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 691

ER -